Head and Neck Cancers with Perineural Invasion

Pericles Ioannides, MD
Allen Chen, MD
University of California, Irvine
CASE I: PRESENTATION

• 68 Year old with slowly progressive painless mass in the right postauricular region

• Symptoms of neuropathic pain without facial nerve palsy

• Did not have advanced cancer which can cause dysphagia, sore throat, referred earache, trismus, numbness, and headache
CASE I: WORKUP

- PET CT showed a 4.3 cm mass with central lucency growing posterolaterally into the region of the soft tissues inferior and posterior to the right EAC.
- MRI showed infiltrating tumor in the right parotid gland with extension to the inferior aspect of the right ear within the deep lobe of the right parotid gland. There is a cystic component noted suggestive of necrosis.
- Biopsy showing fragments of invasive adenoid cystic carcinoma.
- Right partial auriculectomy and parotidectomy showed adenoid cystic carcinoma.
- Extensive perineural invasion (PNI) infiltration of the proximal facial nerve.
- Stage IVA (pT4aN0M0) and referred for adjuvant radiation.
Perineural Invasion

• Tumor invasion of the nerves
  – 3 layers
    • Epineurium
    • Perineurium
    • Endoneurium
  – Categorization
    • Gross
    • Microscopic
Perineural Invasion

• Histologies with high predilection
  – Nasopharyngeal Cancer
  – Paranasal Sinus/Nasal Cavity
  – Soft Tissue Sarcomas
  – Skin Cancers
    • Squamous cell carcinoma
  – Salivary Gland Carcinoma
  – Adenoid cystic
    • Highest association with PNI
    • 1-3 % of head and neck cancer
  – Mucoepidermoid
    • High association with PNI
  – Oral Cavity Cancers
    • Squamous cell carcinoma
    • Large number of cases with perineural spread
  – Melanoma
    • Desmoplastic variant
    • High rate of intracranial extension
Perineural Invasion

• In head and neck cancers tendency to spread along major nerves
• Retrograde conduit for intracranial extension
• Clinically asymptomatic until progression of pain, paresthesia, weakness of mastication can occur
• Predictor for skull base recurrence
LRR increased with PNI

- Multiple reviews showing increase LRR with PNI compared to tumors without PNI

<table>
<thead>
<tr>
<th>Authors</th>
<th>N</th>
<th>Sites</th>
<th>LRR (PNI+)</th>
<th>LRR (PNI-)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tai et al (2011)</td>
<td>190</td>
<td>Oral tongue</td>
<td>22</td>
<td>8</td>
</tr>
<tr>
<td>Hinerman et al (2011)</td>
<td>226</td>
<td>Oral cavity</td>
<td>38</td>
<td>12</td>
</tr>
<tr>
<td>Langendijk et al (2005)</td>
<td>801</td>
<td>Mixed</td>
<td>31</td>
<td>22</td>
</tr>
</tbody>
</table>
PNI with high risk of Base of skull Recurrence

Infra-temporal fossa recurrence

Chen et al, IJROBP 2011
PNI with high risk of Base of skull Recurrence

- Ipsilateral High Cervical Neck

Eisbruch et al, IJROBP 2004
RT reduces rate of Base of Skull Recurrence in tumors with PNI

Base of skull recurrences after treatment of salivary gland cancer with perineural invasion reduced by postoperative radiotherapy

Chen, A.M.,* Garcia, J.,† Granchi, P.,‡ Bucci, M.K.,§ & Lee, N.Y.¶

*Department of Radiation Oncology, University of California, Davis, Cancer Center, Sacramento, CA, USA; †Department of Pathology, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA; ‡Department of Radiology, University of California, Davis, Cancer Center, Sacramento, CA, USA; §Department of Radiation Oncology, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA; and ¶Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Accepted for publication 26 August 2009

Patients with skull base recurrence had 5-year OS of 9% compared to 91% for those without

RT reduced probability of skull base recurrence from 15% to 5% (p=0.03)
At Risk Base of Skull Foramina
Location of Tumor and PNI

• Forehead
  – Supraorbital Nerve $\rightarrow$ V1 $\rightarrow$ Superior orbital Fissure
Location of Tumor and PNI

- **Cheek**
  - Infra-orbital nerve $\rightarrow$ V2 $\rightarrow$ Foramen Rotundum
Location of Tumor and PNI

- Oral Cavity
  - Inferior alveolar nerve/lingual nerve $\rightarrow$ V3 $\rightarrow$ Foramen Ovale
Location of Tumor and PNI

• Ear
  – Facial nerve → Stylomastoid foramen
Location of Tumor and PNI

- Nasopharynx
  - Jacod’s triad
    - Petrosphenoidal Syndrome
    - CN II-VI
  - Villaret Syndrome
    - Postretroparotid space
    - IX, X, XI, XII and sympathetic nerves
Location of Tumor and PNI

- **Parotid Gland**
  - **Anterior**
    - Second maxillary molar
    - Masseter muscle
  - **Posterior**
    - SCM
    - Mastoid Tip
  - **Superior**
    - Zygomatic arch
  - **Inferior**
    - Posterior digastric muscle

- **Facial Nerve (VII)**
  - Brainstem $\rightarrow$ Stylomastoid Foramen $\rightarrow$ Separates parotid to deep superficial and deep lobes
  - Retromandibular vein a common landmark for facial nerve
  - Five branches: Temporal, Zygomatic, Buccal, Marginal Mandibular, and Cervical

- **Auricotemporal Nerve**
  - Branch of V3
  - Innervates parotid gland through parasympathetic control of salivation
  - If damaged by surgery, recovery route to skin causing gustatory sweating (Frey’s syndrome)
Location of Tumor and PNI

- **Submandibular Gland**
  - Superior: Inferior body of mandible
  - Anterior: Anterior belly of the digastric muscle
  - Posterior: Posterior belly of the digastric muscle

- **Hypoglossal Nerve**
  - Medulla → Hypoglossal Canal → between ICA/IJV on the carotid sheath

- **Trigeminal Nerve (V3)**
  - Foramen Ovale → Between Medial and Lateral Pterygoid → Mandibular Foramen → Lingual nerve

- **Facial Nerve**
  - Chorda Tympani innervation
Staging/Degree of PNI

• Worse outcomes with clinical versus microscopic PNI treated with surgery and RT
  – 5 years LC: 87% versus 55% (Garcia-Serra Head Neck 2003)
  – 5 year LC: 90% versus 57% (Jackson Head Neck 2009)
• Cross communication between nerve branches of V and VII
  – 11 patients with PNI of single nerve, recurred with involvement of multiple nerves. Must cover nerve proximally along tract and branches through orbit or masticator space to the base of skull (Gluck IJROBP 2009)
CASE I: SALIVARY CANCER

• Incidence
  – 2,500 cases annually
  – 6% of cases in US

• Classification
  – Major
    • Parotid (75% benign, 25% malignant)
    • Submandibular (50% benign, 50% malignant)
    • Sublingual (25% benign, 75% malignant)
  – Minor
    • Hundreds of mucous-secreting glands beneath mucosal lining of upper aerodigestive tract
CASE I: MALIGNANT SALIVARY GLAND HISTOLOGY

- Mucoepidermoid
  - Most common salivary malignant histology
  - Grade most prognostic
- Adenoid Cystic
  - Most likely to demonstrate PNI
  - Prognosis from best to least is Tubular>cribiform>solid (30% worse)
  - Classic teaching of LN metastasis < 5%
  - Slow growing distant metastasis in up to 50%
  - Late recurrences in > 20 years common
- Adenocarcinoma
  - Nodal metastasis in up to 50-60%
- Actinic cell carcinoma
  - Predominantly in parotid>submandibular
  - Better prognosis in parotid>submandibular
- Carcinoma Ex-pleomorphic
  - Degenerated pleomorphic adenoma
- Salivary duct
  - More common in males (androgen over-expression)
  - Aggressive and higher grade
- Metastasis to salivary gland
  - 5% of salivary malignancies
  - Squamous cell carcinoma and melanoma
- Epithelia-myoeplithelial
  - More common in women typically slow growing
CASE I: WORKUP

- HISTORY AND PHYSICAL
- Size, mobility, and extent of mass
- Meticulous testing of cranial nerves (PNI)
- House Brackman Score
  - Evaluation for degree of facial nerve palsy impairment
    - I (normal)
    - II (Mild dysfunction)
    - III (Moderate Dysfunction)
    - IV (Moderate-severe)
    - V (Severe)
    - IV (Total Paralysis)
CASE I: WORKUP

• Ultrasound
• Fine Needle Aspiration
  – Sensitivity 80%
  – Specificity 95%
• MRI with contrast
  – Evaluation of perineural involvement
• CT chest
  – Malignant histologies
• Dental, nutrition, speech/swallow
**Table 8**
American Joint Committee on Cancer (AJCC)
(Parotid, Submandibular, and Sublingual)

<table>
<thead>
<tr>
<th>Primary Tumor (T)</th>
<th>Regional Lymph Nodes (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>NX</td>
</tr>
<tr>
<td>T0</td>
<td>N0</td>
</tr>
<tr>
<td>Tis</td>
<td>N1</td>
</tr>
<tr>
<td>T1</td>
<td>N2</td>
</tr>
<tr>
<td>T2</td>
<td>N2a</td>
</tr>
<tr>
<td>T3</td>
<td>N2b</td>
</tr>
<tr>
<td>T4</td>
<td>N2c</td>
</tr>
<tr>
<td>T4a</td>
<td>N3</td>
</tr>
<tr>
<td>T4b</td>
<td>N3a</td>
</tr>
<tr>
<td></td>
<td>N3b</td>
</tr>
</tbody>
</table>

- **Primary Tumor (T)**
  - **TX**: Primary tumor cannot be assessed
  - **T0**: No evidence of primary tumor
  - **Tis**: Carcinoma in situ
  - **T1**: Tumor 2 cm or smaller in greatest dimension without extraparenchymal extension
  - **T2**: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension without extraparenchymal extension
  - **T3**: Tumor larger than 4 cm and/or tumor having extraparenchymal extension
  - **T4**: Moderately advanced or very advanced disease
    - **T4a**: Moderately advanced disease (Tumor invades skin, mandible, ear canal, and/or facial nerve)
    - **T4b**: Very advanced disease (Tumor invades skull base and/or pterygoid plates and/or encases carotid artery)

- **Regional Lymph Nodes (N)**
  - **NX**: Regional lymph nodes cannot be assessed
  - **N0**: No regional lymph node metastasis
  - **N1**: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)
  - **N2**: Metastasis in a single ipsilateral lymph node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(-), or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
  - **N2a**: Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)
  - **N2b**: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)
  - **N2c**: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
  - **N3**: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) with clinically overt ENE(+)
    - **N3a**: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)
    - **N3b**: Metastases in any node(s) with clinically overt ENE(+)

**Note**: A designation of "U" or "L" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(-) or ENE(+).
STAGING

Table 8 — Continued
American Joint Committee on Cancer (AJCC)
(Parotid, Submandibular, and Sublingual)

Regional Lymph Nodes (N)
Pathological N (pN)

NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less smaller in greatest
dimension and ENE(-)
N2 Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest
dimension and ENE(+) or larger than 3 cm but not larger than 6 cm in greatest
dimension and ENE(-); or metastases in multiple ipsilateral lymph node(s), none
larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral
lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
N2a Metastasis in a single ipsilateral lymph node 3 cm or smaller in greatest
dimension and ENE(+) or a single ipsilateral node larger than 3 cm but not larger than 6 cm
in greatest dimension and ENE(-)
N2b Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest
dimension and ENE(-)
N2c Metastasis in bilateral or contralateral lymph node(s), none more than 6 cm in
greatest dimension and ENE(-)
N3 Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or
in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+) or
multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+) or a single
contralateral node of any size and ENE(+)
N3a Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)
N3b Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and
ENE(+) or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+) or
a single contralateral node of any size and ENE(+)

Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis

Anatomic Stage/Prognostic Groups
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3 N0 M0
T0, T1, T2, T3 N1 M0
Stage IVA T0 N2 M0
T1 N2 M0
T2 N2 M0
T3 N2 M0
T4a N0, N1, N2 M0
Stage IVB Any T N3 M0
T4b Any N M0
Stage IVC Any T Any N M1
CASE I: Studies

- Surgery
  - Standard of care definitive treatment
    - Superficial parotidectomy for low grade tumors
  - Minimize tumor spillage
  - Preservation of functional cranial nerves
    - Graft if sacrificed
    - Complication of facial nerve palsy of Frey’s syndrome (gustatory flushing)
  - Elective nodal dissection optional
    - Parotid: II-IV
    - Submandibular: I-III
  - Clinically positive neck should be dissected
    - Parotid: I-V at risk
CASE I: Studies

• Postoperative Radiation
  – Indications:
    • T3-4, close or positive margins, high grade, recurrent disease, positive lymph nodes, PNI, LVSI, adenoid cystic histology, and bone invasion
    – In a review (Terhaard, Head and Neck 2005) showed improved 10 year local control after surgery for salivary high risk features
      • T3-4 (18 to 84%)
      • < 5 mm margin (55 to 95%)
      • Positive Margin (44 to 82%)
      • Bone invasion (55 to 86%)
      • PNI (60 to 88%)
  – Improved CSS and LC in stage III-IV patients (Armstrong (Arch Otolaryngol Head Neck Surg)
  – Improved 5 year OS in facial nerve palsy, undifferentiated histology, male, skin involvement (North IJROBP 2990)
CASE I: Studies

• Definitive Radiation
  • Photons
    – 10 year LC of 17 to 57% (Mendehall Cancer 2005, Chen IJROBP 2007, Cinchetti et al., Wang et al, Laramore et al)
    – Evidence of doses > 70 Gy with better outcomes (Mendenhall Cancer 2005)
    – Use of modern techniques with small retrospective study with IMRT at MSKCC show 5 year LRC of 47% (Spratt Radiol Oncol 2014)
  • Elective Nodal Irradiation
    – Highest incidence in high grade, LVSI, PNI, higher T-stage, and histology with up to up to 15-45% of patients with clinically node negative being node positive at time of resection and therefore should be included in high risk tumors (Xiao NCDB Arch Otol HN Surg 2016; Stennert, Arch Otol HN Surg 2003; Yoo, Korea J Surg Oncol 2015)
  • Neutrons
    – Proposed as means to improve outcome due to higher RBE (> 2.6) compared to photons that may be advantageous in particularly adenoid cystic due to low GF and low doubling time but with significant toxicity and cost
    – RTOG 80-01 compared photon/electron therapy with neutron therapy with 32 patients showing improved LC (17% to 56%) leading to early closure of trial, but NSD In OS but severe late complication in 69% of neutron patients compared to 15% of photons. Criticized for small number of patients, differences in histology, and tumor size imbalances
    – University of Washington showed CSS and LRC of 67% and 59% at 6 years, with 10% G3-4 toxicity at 6 years (Douglas Arch Otolaryngol Head Neck Surg 2003)
CASE I: Studies

- **Chemotherapy**
  - No prior prospective trials to date and remains controversial
  - Response rates
    - 35-38% with cisplatin based chemotherapy for recurrent and advanced salivary gland cancer
  - **Evidence For:**
    - Pair analysis of 24 patients showed improved 3 year OS with chemoradiation from 44 to 83% but increased grade 3 toxicity (Tanvetyanon Arch Otolaryngol Head Neck Surg)
    - Propensity score matched 93 patients of adenoic cystic salivary gland with surgery and postoperative radiation versus chemoradiation (cisplatin based) showed 8 year LRC improved from 67 to 97%) but no difference in OS (Hsieh Radiat Oncol 206)
  - **Evidence Against:**
    - NCDB analysis of G2-3 salivary gland with one adverse feature after resection showed inferior 5 year OS with chemoradiation compared to RT alone (54 to 28%) (Amini NCDB JAMA Otolaryngol Head Neck Surg 2016)
    - Targeted agents (Imatanib/Lapitanib/Dasatinib) in phase II trials without much benefit (Hotte PMH Jclin Oncol 2005; Agulnik JCO 2007; Wong Ann Oncol 2016)
  - **Investigational**
    - RTOG 1008 for high risk major salivary gland carcinoma comparing postoperative chemoradiation versus radiation alone
CASE1: SIMULATION

• Position
  – Supine with neck extended
  – Shoulders down

• Immobilization
  – Thermoplastic head and shoulder mask
  – Bite Block and Tongue blade

• Localization
  – Wire Scar
  – Bolus for skin invasion
  – MRI/PET-CT fusion for primary tumor and for nerve localization
CASE 1: TARGET

- **GTV**
  - All gross residual disease and involved nodes
  - Surgical bed

- **CTV**
  - 70 Gy
    - Gross residual disease
  - 66 Gy
    - Close Positive Margins
    - ENE
  - 60 Gy
    - Primary site, surgical clips, graft, edema, and areas of involved nodal disease
    - Parapharyngeal space/retrostyloid (T3-T4)
    - CN V3, VII, XII to base of skull foramina (Adenoid cystic)
    - VII treated through stylomastoid foramen to base of skull (Parotid with PNI)
  - 54 Gy
    - Node negative ipsilateral cervical neck, supraclavicular neck if necessary
    - At risk nerves back to base of skull

- **PTV**
  - CTV + 3 mm with daily IGRT imaging
CASE 1: TECHNIQUE

• IMRT
  – Recommended for large postoperative beds or extended neck coverage

• Conventional
  – Wedged pair photon beams
  – Mixed photon/electron beam
  – Angle Obliquely to keep off spinal cord
  – Superior half-beam block to match primary field
CASE 1: IMRT PLAN

ASSOCIATION OF RESIDENTS IN RADIATION ONCOLOGY

July 23, 2019
OAR (Recommended)

- Brainstem: max 54 Gy
- Optic chiasm: max 45 Gy
- Cochlea: max 45 Gy
- Mandible: limit V70 < 1%
- Temporal lobe: Max < 60
- Optic Nerve: Max < 54 Gy
- Retina: Max < 45 Gy
- Contralateral Parotid: Mean < 26 Gy
- Submandibular Gland: Mean < 39 Gy
- Pharyngeal Constrictors: Mean < 45 Gy
- Middle Ear: Max < 50 Gy
- Larynx: Mean < 40 Gy
- True Vocal Cords: Max < 25 Gy
- Temporal Mandibular Joint: Mean < 45 Gy
- Lacrimal Gland: V30< 50%
- Lens: Max < 10 gy
CASE II: Oral Cavity

- 65 year-old male s/p surgery for T4N0 (4.5 cm) SCC of left gingiva region with negative margins, high grade, invasion of the mandible, with significant PNI
Case II: Oral Cavity

- Patient was treated with IMRT
  - 60 Gy to the primary resection bed
  - 54 Gy to the bilateral neck and nerve tracts
    - Covered the inferior alveolar nerve from retrograde pathway → Mandibular Foramen → V3 → Foramen ovale of the base of skull

July 23, 2019
Follow-up

• H&P
  – Every 1–2 months for year 1
  – Every 3 months for years 2–3
  – Every 6 months for years 4–5,
  – Annually after 5 years

• MRI at 6 months and again as indicated

• TSH every 6-12 months if neck irradiated
Suggested Atlas for RT coverage of head and neck cancers with PNI


Conclusion

• Perineural invasion for head and neck cancers is associated with high risk of local regional and base of skull recurrence

• Postoperative RT should be offered in cases of PNI with coverage of at risk nerves to the base of skull
References


Please provide feedback regarding this case or other ARROcases to arrocase@gmail.com